Lupus Nephritis Treatment Market Growth Opportunities and Forecast till 2030
The global Lupus Nephritis Treatment market Size was valued at USD 4,392 Million in 2021 and is anticipated to reach USD 8,048 Million by 2030 with a CAGR of 7.3% from 2022 to 2030.
Lupus nephritis is kidney inflammation and damage attributable to systemic lupus erythematosus (SLE). Lupus is the most frequent type of lupus. Lupus is an autoimmune disorder in which your immune system attacks your tissues. Lupus can harm your brain, heart, joints, skin, and other organs in addition to your kidneys. Lupus nephritis is kidney inflammation caused by the inflammatory illness lupus. Fluid retention in your body and increased urine output can be symptoms. Lupus nephritis affects around half of grownups and 80% of children with lupus. Lupus nephritis affects up to 60% of lupus patients. When the kidneys become inflamed, they lose their ability to operate normally and can leak protein. Lupus nephritis can progress to renal failure if not treated.
Lupus Nephritis Treatment Market
Lupus Nephritis Treatment Market Size in 2021
US$ 4,392 Million
Lupus Nephritis Treatment Market Forecast By 2030
US$ 8,048 Million
Lupus Nephritis Treatment Market CAGR During 2022 – 2030
Lupus Nephritis Treatment Market Analysis Period
2018 - 2030
Lupus Nephritis Treatment Market Base Year
Lupus Nephritis Treatment Market Forecast Data
2022 - 2030
By Drug Class, By Route of Administration, and By Region
Lupus Nephritis Treatment Market Regional Scope
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled
Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and Sanofi.
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
Lupus is treated with medications that suppress immune system. Steroids (corticosteroids) and antimalarial medicines are examples of these. Everyone is unique, and your doctor will devise a treatment plan tailored to your specific needs. A mix of therapy may be used. Corticosteroids (often known as "steroids"), immunosuppressive medications, ACE inhibitors and ARBs, monoclonal antibodies, diuretics, and dietary changes are common treatments for lupus nephritis.
In 1964, the World Health Organization (WHO) devised a classification system for the five stages of lupus nephritis. The International Society of Nephrology and the Renal Pathology Society created new classification levels in 2003.
Lupus nephritis has no known treatment. The purpose of treatment is to prevent the condition from worsening. Stopping kidney disease early can help you avoid needing a kidney transplant. Lupus symptoms might also be alleviated with treatment. Common treatments include limiting your protein and salt intake, taking blood pressure medication, using steroids like prednisone (Rayos) to minimise swelling and inflammation, and using immune suppressing medications like mycophenolate-mofetil or cyclophosphamide (CellCept).
A kidney biopsy, blood testing, and urine analysis are used to diagnose lupus nephritis. A urine sample is used by a medical expert to check for blood and protein in the urine. Kidney injury is indicated by a high quantity of protein or a high concentration of red blood cells in the urine. Additionally, a microscope will be used to look for kidney cells in the urine.
A blood test is used by medical professionals to assess your kidney function. Creatinine, a waste product from the body's typical breakdown of muscles, is measured by the blood test. The kidneys of the patient filter the blood of creatinine. Your glomerular filtration rate is determined by the amount of creatinine in your blood by medical specialists (GFR). Creatinine levels increase as kidney disease worsens.
During a kidney biopsy, a small sample of kidney tissue is removed for microscopic examination. In a hospital setting, a clinician does the biopsy while employing imaging methods to direct the biopsy needle into the kidney, such as ultrasound or computed tomography (CT) scanning.
The three categories of the global lupus nephritis treatment market are drug class, route of administration, and region. Drug Class segment can be further divided into NSAIDs, corticosteroids, anti malarial, immunosuppressant’s, and biologics. Among them, the immunosuppressant’s sub-segment generated the largest market shares in 2021. According to the American Journal of Kidney Diseases, immunosuppressive medications such as azathioprine and cyclophosphamide have become widely used in the treatment of patients with lupus nephritis over the past 20 years. Furthermore, oral, intravenous, and subcutaneous are the segregation of Route of Administration segment. Based on our industry analysis, oral sub-segment achieved a substantial market share from 2022 to 2030.
Global Lupus Nephritis Treatment Market Geographical Competition
The North American, European, Latin American, Asian Pacific, and Middle Eastern & African regions make up the five geographical segments of the worldwide Lupus nephritis treatment market. During the projected period, North America is anticipated to dominate the global lupus nephritis market. The rising incidence of lupus nephritis in this area has fueled market expansion there. Along with stronger healthcare infrastructure and coverage for specialty pharmaceuticals, the high frequency of lupus nephritis adds to the expansion of the North American area for the lupus nephritis market. The Lupus Foundation of America estimates that 1.5 million Americans and at least 5 million other people worldwide suffer from lupus nephritis. Women make up 90% of those who have lupus nephritis patients.
Global Lupus Nephritis Treatment Industry Segment Analysis
Market By Drug Class
· Anti Malarial
Market By Route of Administration
Lupus Nephritis Treatment Market Leading Companies
This section of the study honors the market's top vendors Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi.
Lupus Nephritis Treatment Market Regions
· Rest of Europe
· Rest of Latin America
· South Korea
· Rest of Asia-Pacific
Middle East & Africa
· South Africa
· Rest of Middle East & Africa